Catherine M Kelly

9PUBLICATIONS
81CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Environmental epidemiologyHealth informatics and information systems
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Apr 10, 2025
BRCA1/2 and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2- Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis.

Eric Hahnen, Jan Hauke, Karen Gelmon

|Nov 12, 2024
Clinical Management of Ovarian Function Suppression in Premenopausal Women With Breast Cancer: A Survey of Members of ASCO.

Catherine M Kelly, Kathleen E Bennett, Caitriona Cahir

|Sep 23, 2024
The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer.

Matteo Dugo, Chiun-Sheng Huang, Daniel Egle

|Jun 21, 2024
Quality of life in women with early-stage and metastatic hormone receptor-positive, HER2-negative breast cancer receiving endocrine therapy.

David O'Reilly, Abdul Rehman Farooq, Paul Nevins Selvadurai

|May 18, 2023
Impact of COVID-19 on health care and quality of life in women with breast cancer.

Charlotte Myers, Kathleen Bennett, Catherine Kelly

|Aug 24, 2022
Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical Insights.

Mairi W Lucas, Catherine M Kelly

Pageof 2

Frequent Collaborators

2 joint publications

Frederik Marmé

2 joint publications

Angela DeMichele

2 joint publications

Michael Untch

2 joint publications

Karen Gelmon